Walleye Capital’s Legend Biotech LEGN Stock Holding History

Walleye Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27M	Sell	70,100 -25,800	-27%	-$492K	0.01%	1865
2025 Q4	$2.08M	Buy	95,900 +81,100	+548%	+$2.32M	0.01%	1840
2025 Q3	$483K	Buy	14,800 +6,100	+70%	+$225K	﹤0.01%	2643
2025 Q2	$309K	Sell	8,700 -400	-4%	-$13K	﹤0.01%	3029
2025 Q1	$309K	Buy	9,100 +800	+10%	+$28.7K	﹤0.01%	2931
2024 Q4	$270K	Sell	8,300 -14,400	-63%	-$596K	﹤0.01%	3516
2024 Q3	$1.11M	Sell	22,700 -75,900	-77%	-$4.04M	﹤0.01%	2558
2024 Q2	$4.37M	Buy	98,600 +94,200	+2,141%	+$4.35M	0.01%	1387
2024 Q1	$247K	Sell	4,400 -5,000	-53%	-$302K	﹤0.01%	3825
2023 Q4	$566K	Buy	9,400 +5,400	+135%	+$342K	﹤0.01%	2843
2023 Q3	$269K	Buy	+4,000	New	+$278K	﹤0.01%	3327
2022 Q4	–	Sell	-100	Closed	-$4K	–	3435
2022 Q3	$4K	Buy	+100	New	+$4.69K	﹤0.01%	2964

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FBIL

First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Walleye Capital's LEGN Position: Q1 2026 in Review

Walleye Capital reduced its Legend Biotech (LEGN) stake by 21% in Q1 2026, selling an estimated $1.22M and leaving 235,415 shares worth $4.26M. The position accounts for 0.02% of the portfolio, ranked #903.

Walleye Capital first reported a position in LEGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $6.51M in Q4 2025. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

Walleye Capital held 235,415 shares of Legend Biotech worth $4.26M as of Q1 2026.
Walleye Capital sold 64,048 Legend Biotech shares in Q1 2026, an estimated $1.22M.
Legend Biotech made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #903 holding.
Walleye Capital first reported a position in Legend Biotech in Q1 2024 and has held it in 9 quarters since.
Walleye Capital's Legend Biotech position peaked at $6.51M in Q4 2025.
189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.